Država: Irska
Jezik: angleščina
Source: HPRA (Health Products Regulatory Authority)
Rifampicin
Sanofi-Aventis Ireland Limited T/A SANOFI
J04AB; J04AB02
Rifampicin
150 milligram(s)
Capsule, hard
Product subject to prescription which may not be renewed (A)
Antibiotics; rifampicin
Not marketed
1977-02-14
Internal RIFADIN® 150MG CAPSULES _Rifampicin _ IS THIS LEAFLET HARD TO SEE OR READ? PHONE 01 403 5600 FOR HELP. Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any side effects gets serious, or if you notice any side effect not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What Rifadin is and what it is used for 2. Before you take Rifadin 3. How to take Rifadin 4. Possible side effects 5. How to store Rifadin 6. Further information 1. WHAT RIFADIN IS AND WHAT IT IS USED FOR 1. WHAT RIFADIN IS AND WHAT IT IS USED FOR Rifadin 150mg Capsules are one of a group of medicines called antibiotics. They are used to treat tuberculosis (also known as TB), and are active against some other organisms. 2. BEFORE YOU USE RIFADIN 2. BEFORE YOU TAKE RIFADIN DO NOT TAKE RIFADIN IF: - You are allergic (hypersensitive) to rifampicin or any of the other ingredients. - You have yellowing of the skin and eyes (jaundice). - You are taking saquinavir or ritonavir for HIV infection (see ‘Taking other medicines’ section below). Do not take if any of the above apply to you. If you are not sure, talk to your doctor, nurse or pharmacist before taking Rifadin. WARNINGS AND PRECAUTIONS INFORM YOUR DOCTOR IMMEDIATELY WHILE TAKING THIS MEDICINE • If your symptoms of tuberculosis return or get worse (see 4. Possible side effects) • if you develop new or sudden worsening of shortness of breath, possibly with a dry cough or fever not responding to antibiotic treatment. These could be symptoms of lung inflammation (interstitial lung disease/pneumonitis) and can lead to serious breathing problems due to collection of fluid in the lungs and interfere with normal breathing which can lead to life threatening conditions Intern Preberite celoten dokument
Health Products Regulatory Authority 14 March 2024 CRN00DR74 Page 1 of 12 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Rifadin 150mg Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains Rifampicin 150 mg. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Hard capsules (Capsules). Opaque, hard gelatin capsule with scarlet body and light blue cap, marked R-150. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Indications for use: Rifadin, used in combination with other active anti-tuberculosis drugs, is indicated in the treatment of tuberculosis and certain other mycobacterial infections. Rifadin is active _in vitro_ at low concentrations against Gram-positive organisms and _N. Gonorrhoea._ 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Recommended Dosage For oral administration. The daily dose of Rifadin, calculated from the patient’s body weight, should preferably be taken on an empty stomach at least 30 minutes before a meal or 2 hours after a meal to ensure rapid and complete absorption. Rifadin should be given with other effective anti-tuberculosis drugs to prevent the possible emergence of rifampicin-resistant strains of Mycobacteria. _Adults_: The recommended single daily dose in tuberculosis is 450mg to 600mg (10mg/kg bodyweight). _Usual Daily dose_: Patients weighing less than 50kg – 450mg. Patients weighing 50kg or more – 600mg. _Children_: In children over 3 months, oral doses of 15 (10-20) mg/kg bodyweight daily are recommended, although a total daily dose should not exceed 600mg. Impaired liver function: A daily dose of 8mg/kg should not be exceeded in patients with impaired liver function. Use in the elderly: Caution should be exercised in using Rifampicin in such patients especially if there is evidence of liver function impairment. 4.3 CONTRAINDICATIONS Health Products Regulatory Authority 14 March 2024 CRN00DR74 Page 2 of 12 Rifadin is contra-indicated in the presence of jaundice, and in patients who are hypersensitive to the rifamyc Preberite celoten dokument